Table of Contents
International Journal of Molecular Imaging
Volume 2011, Article ID 279345, 6 pages
http://dx.doi.org/10.1155/2011/279345
Research Article

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

1Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, 141 86 Stockholm, Sweden
2Department of Radiology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden
3Department of Nuclear Medicine, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
4Division of Surgery, Karolinska Institute at Campus Huddinge, 141 86 Stockholm, Sweden

Received 28 June 2010; Revised 2 September 2010; Accepted 20 January 2011

Academic Editor: Domenico Rubello

Copyright © 2011 Gunnar Herlin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Falk, H. Carstens, L. Lundell, and M. Albertsson, “Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences,” Acta Oncologica, vol. 46, no. 8, pp. 1070–1074, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. J. Kim, H. Y. Kim, K. W. Lee, and M. S. Kim, “Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy,” Radiographics, vol. 29, no. 2, pp. 403–421, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. J. Savides, “Endosonography: new developments,” Current Opinion in Gastroenterology, vol. 25, no. 5, pp. 428–432, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. C. Sabbagh, “Esophageal cancer,” Gastrointestinal Endoscopy, vol. 69, no. 2, supplement, pp. S93–S96, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. T. Attila and D. O. Faigel, “Role of endoscopic ultrasound in superficial esophageal cancer,” Diseases of the Esophagus, vol. 22, no. 2, pp. 104–112, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. Kahn, Y. Menda, K. Kernstine et al., “The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer,” Chest, vol. 125, no. 2, pp. 494–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Ferran, Y. Ricart, M. Lopez et al., “Characterization of radiologically indeterminate lung lesions: 99mTc-depreotide SPECT versus 18F-FDG PET,” Nuclear Medicine Communications, vol. 27, no. 6, pp. 507–514, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Halley, A. Hugentobler, P. Icard et al., “Efficiency of F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 9, pp. 1026–1032, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Blum, H. Handmaker, J. Lister-James, and N. Rinne, “A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules,” Chest, vol. 117, no. 5, pp. 1232–1238, 2000. View at Google Scholar · View at Scopus
  10. T. Martins, J. Sena Lino, S. Ramos, and L. Oliveira, “Tc-depreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience,” Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 2, pp. 253–259, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. Axelsson, G. Herlin, M. Bååth, P. Aspelin, and K. G. Kölbeck, “Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer,” Acta Radiologica, vol. 49, no. 3, pp. 295–302, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. D. J. Kwekkeboom and E. P. Krenning, “Somatostatin receptor imaging,” Seminars in Nuclear Medicine, vol. 32, no. 2, pp. 84–91, 2002. View at Google Scholar · View at Scopus
  13. J. C. Reubi, J. Laissue, E. Krenning, and S. W. J. Lamberts, “Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications,” Journal of Steroid Biochemistry and Molecular Biology, vol. 43, no. 1–3, pp. 27–35, 1992. View at Google Scholar · View at Scopus
  14. I. Virgolini, M. Leimer, H. Handmaker et al., “Somatostatin receptor subtype specificity and in viva binding of a novel tumor tracer, 99mTc-P829,” Cancer Research, vol. 58, no. 9, pp. 1850–1859, 1998. View at Google Scholar · View at Scopus
  15. G. Herlin, K. G. Klbeck, P. L. Menzel et al., “Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations,” Acta Radiologica, vol. 50, no. 8, pp. 902–908, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. E. Shrout and J. L. Fleiss, “Intraclass correlations: uses in assessing rater reliability,” Psychological Bulletin, vol. 86, no. 2, pp. 420–428, 1979. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Shinya, K. Rai, Y. Okumura et al., “Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer,” Clinical Nuclear Medicine, vol. 34, no. 4, pp. 216–221, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Y. K. Chen, Y. Y. Shen, and C. H. Kao, “Dual-phase F-18 FDG PET cannot increase the diagnostic accuracy to differentiate solitary pulmonary nodules,” Clinical Nuclear Medicine, vol. 29, no. 4, pp. 281–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Sukan, M. Reyhan, M. Aydin et al., “Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging,” Annals of Nuclear Medicine, vol. 22, no. 2, pp. 123–131, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. J. Chen, BI. F. Lee, W. J. Yao et al., “Dual-phase F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5,” American Journal of Roentgenology, vol. 191, no. 2, pp. 475–479, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Gabriel, C. Decristoforo, D. Kendler et al., “Ga-DOTA-Tyr-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 508–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. C. Reubi, J. C. Schär, B. Waser et al., “Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 273–282, 2000. View at Google Scholar · View at Scopus
  23. D. J. Kwekkeboom, B. L. Kam, M. Van Essen et al., “Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R53–R73, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. J. M. Teunissen, D. J. Kwekkeboom, and E. P. Krenning, “Quality of life in patients with gastroenteropancreatic tumors treated with [Lu-DOTA,Tyr]octreotate,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2724–2729, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus